Halyard Health, Inc. operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management. Its products include post-operative pain management solutions, minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. This segment sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and other brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. Halyard Health, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:HYH
CUSIPN/A
Phone678-425-9273
Debt
Debt-to-Equity Ratio0.43
Current Ratio3.22
Quick Ratio2.96
Price-To-Earnings
Trailing P/E Ratio24.36
Forward P/E Ratio32.71
P/E Growth3.68
Sales & Book Value
Annual Sales$611.60 million
Price / Sales4.40
Cash Flow$1.2427 per share
Price / Cash46.07
Book Value$25.95 per share
Price / Book2.21
Profitability
EPS (Most Recent Fiscal Year)$2.35
Net Income$79.30 million
Net Margins7.72%
Return on Equity7.90%
Return on Assets4.38%
Miscellaneous
Employees13,000
Outstanding Shares47,020,000
Market Cap$2,691.70
Halyard Health (NYSE:HYH) Frequently Asked Questions
What is Halyard Health's stock symbol?
Halyard Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HYH."
How were Halyard Health's earnings last quarter?
Halyard Health (NYSE:HYH) posted its quarterly earnings data on Wednesday, May, 2nd. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.59. The medical instruments supplier earned $156.40 million during the quarter, compared to the consensus estimate of $155.08 million. Halyard Health had a net margin of 7.72% and a return on equity of 7.90%. The firm's revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.48 EPS. View Halyard Health's Earnings History.
What guidance has Halyard Health issued on next quarter's earnings?
Halyard Health updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided EPS guidance of $1.65-$1.85 for the period, compared to the Thomson Reuters consensus estimate of $1.26.
What price target have analysts set for HYH?
5 equities research analysts have issued 1-year target prices for Halyard Health's shares. Their forecasts range from $50.00 to $67.00. On average, they anticipate Halyard Health's share price to reach $59.25 in the next twelve months. This suggests a possible upside of 3.5% from the stock's current price. View Analyst Ratings for Halyard Health.
What is the consensus analysts' recommendation for Halyard Health?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halyard Health in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Halyard Health's key competitors?
Some companies that are related to Halyard Health include WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Wright Medical Group (WMGI), CONSORT Med PLC/S (CSRMY), Invacare (IVC), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), Histogenics (HSGX), Rewalk Robotics (RWLK), NanoVibronix (NAOV) and COLLPLANT HOLDI/S (CLGN).
Who are Halyard Health's key executives?
Halyard Health's management team includes the folowing people:
- Mr. Steven E. Voskuil, Sr. VP & CFO (Age 50)
- Mr. John W. Wesley, Sr. VP & Gen. Counsel (Age 59)
- Ms. Rhonda D. Gibby, Sr. VP & Chief HR Officer (Age 50)
- Mr. Joseph F. Woody, CEO & Director (Age 52)
- Mr. Renato Negro, VP, Controller & Chief Accounting Officer
Has Halyard Health been receiving favorable news coverage?
Press coverage about HYH stock has been trending somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Halyard Health earned a daily sentiment score of 0.02 on Accern's scale. They also gave press coverage about the medical instruments supplier an impact score of 46.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Halyard Health's major shareholders?
Which major investors are buying Halyard Health stock?
How do I buy shares of Halyard Health?
Shares of HYH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halyard Health's stock price today?
One share of HYH stock can currently be purchased for approximately $57.25.
How big of a company is Halyard Health?
Halyard Health has a market capitalization of $2.69 billion and generates $611.60 million in revenue each year. The medical instruments supplier earns $79.30 million in net income (profit) each year or $2.35 on an earnings per share basis. Halyard Health employs 13,000 workers across the globe.
How can I contact Halyard Health?
Halyard Health's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The medical instruments supplier can be reached via phone at 678-425-9273 or via email at [email protected]
MarketBeat Community Rating for Halyard Health (NYSE HYH)
MarketBeat's community ratings are surveys of what our community members think about Halyard Health and other stocks. Vote "Outperform" if you believe HYH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HYH will underperform the S&P 500 over the long term. You may vote once every thirty days.
